PAB
$10M17mo
Patrys
Biotech · Oncology
Deoxymabs (cell-penetrating antibodies) targeting intracellular DNA damage repair for cancer
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.9M
Dec 2025 4C
Runway
17moADEQUATE
Based on Dec 2025 4C
Market Cap
$10M
Burn Rate
$0.3M/qtr
Dec 2025 4C
Shares Outstanding
341M
Pipeline Assets
1
Latest Insights(2)
19 Apr 2026Capital RaiseProposed issue of securities - PAB
$3.2MPlacement·at$0.024·133.3M shares
Capital Raise$3.2 million Placement to Advance Clinical Trials
$3.2MPlacement·at$0.024·133.0M shares
Lead: Templar Corporate Pty Ltd
3M Price
PAB.ASX$0.029-3.3% 3M
Low $0.025High $0.041
Pipeline Assets (1)
PAT-DX1Solid tumours (deoxymab)
Phase 1Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
PAT-DX1
Solid tumours (deoxymab)
Capital Raises & Buybacks
2 raises
Current shares outstanding: 341M
Placement
2026-04-20placement
$3.2M
2026-04-20placement
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Catalysts (2)· 1 upcoming · 1 past
Expectedarrow_upwardHigh31 Dec 2026
expand_more1 past catalyst
ConfirmedremoveMed10 Mar 2026
Patrys has initiated engagement with a US regulatory affairs advisor to support an FDA pre-IND submission for RLS-2201, a proprietary injectable formulation of Quetiapine for the treatment of delirium. The company is preparing regulatory documentation and defining its clinical development strategy ahead of a planned Phase 0 clinical trial in H2 2026.
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Announcements(9)
trending_up
Capital RaisePSauto_awesome
$3.2 million Placement to Advance Clinical Trials19 Apr 2026
expand_more319KB